↓ Skip to main content

Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factors

Overview of attention for article published in BMC Cancer, March 2016
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
29 Dimensions

Readers on

mendeley
46 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factors
Published in
BMC Cancer, March 2016
DOI 10.1186/s12885-016-2271-8
Pubmed ID
Authors

Ko Sato, Satoshi Watanabe, Aya Ohtsubo, Satoshi Shoji, Daisuke Ishikawa, Tomohiro Tanaka, Koichiro Nozaki, Rie Kondo, Masaaki Okajima, Satoru Miura, Junta Tanaka, Takuro Sakagami, Toshiyuki Koya, Hiroshi Kagamu, Hirohisa Yoshizawa, Ichiei Narita

Abstract

Nephrotoxicity is the major side effect that limits the dose of cisplatin that can be safely administered, and it is a clinical problem in cancer patients who received cisplatin combination chemotherapy. Recent evidence has demonstrated that patients with chronic kidney disease (CKD) have an increased risk of developing acute kidney injury (AKI). The present study was conducted to evaluate the prevalence of CKD risk factors in patients who received cisplatin and to assess the correlation between CKD risk factors and cisplatin-induced AKI. We retrospectively analyzed 84 patients treated with cisplatin combination chemotherapy for thoracic malignancies. AKI was defined as a decrease in the estimated glomerular filtration rate (eGFR) > 25 % from base line, an increase in the serum creatinine (sCre) level of > 0.3 mg/dl or ≥ 1.5 times the baseline level. Eighty of the 84 patients (95.2 %) had at least one risk factor for CKD. All enrolled patients received cisplatin with hydration, magnesium supplementation and mannitol. Cisplatin-induced AKI was observed in 18 patients (21.4 %). Univariate analysis revealed that cardiac disease and use of non-steroidal anti-inflammatory drugs (NSAIDs) were associated with cisplatin-induced nephrotoxicity (odds ratios [OR] 6 and 3.56, 95 % confidence intervals [CI] 1.21-29.87 and 1.11-11.39, p = 0.04 and p = 0.04, respectively). Multivariate analysis revealed that cisplatin nephrotoxicity occurred significantly more often in patients with both risk factors (OR 13.64, 95 % CI 1.11-326.83, p = 0.04). Patients with more risk factors for CKD tended to have a greater risk of developing cisplatin-induced AKI. We should consider avoiding administration of cisplatin to patients with CKD risk factors, particularly cardiac disease and NSAID use.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 46 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 46 100%

Demographic breakdown

Readers by professional status Count As %
Other 7 15%
Student > Postgraduate 6 13%
Student > Bachelor 6 13%
Student > Master 4 9%
Student > Ph. D. Student 3 7%
Other 7 15%
Unknown 13 28%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 8 17%
Medicine and Dentistry 8 17%
Nursing and Health Professions 4 9%
Agricultural and Biological Sciences 3 7%
Biochemistry, Genetics and Molecular Biology 2 4%
Other 5 11%
Unknown 16 35%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 March 2016.
All research outputs
#5,614,228
of 7,419,920 outputs
Outputs from BMC Cancer
#2,103
of 3,251 outputs
Outputs of similar age
#194,697
of 276,994 outputs
Outputs of similar age from BMC Cancer
#95
of 166 outputs
Altmetric has tracked 7,419,920 research outputs across all sources so far. This one is in the 13th percentile – i.e., 13% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,251 research outputs from this source. They receive a mean Attention Score of 3.3. This one is in the 18th percentile – i.e., 18% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 276,994 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 166 others from the same source and published within six weeks on either side of this one. This one is in the 21st percentile – i.e., 21% of its contemporaries scored the same or lower than it.